

- i. Ashby, Brad (014179)

V. INTERAGENCY/PROFESSIONAL ASSOCIATIONS

VI. BOARD REPORTS

- A. Executive Director
 - a. eMars
 - b. Cost of Dispensing Study Update*
 - c. Legislative Update
- B. General Counsel
 - a. Ethics Review
 - b. Regulation Update

VII. COMMITTEE REPORTS

- A. Advisory Council
 - i. 201 KAR 2:045
 - ii. 201 KAR 2:380
- B. KYPRN*
- C. Protocol Review Committee
 - i. Anaphylaxis Treatment Protocol for Emergency Epinephrine Devices v4
 - ii. Colorectal Cancer (CRC) Screening Protocol v2
 - iii. HIV Pre-Exposure Prophylaxis (PrEP) Protocol v2
- D. CE Advisory Committee
 - i. March 5, 2026, meeting board approved CE recommendations

VIII. OLD BUSINESS

- A. Farmakeio AR- Application Revisit (GRAV-HBCOHF)

IX. NEW BUSINESS

- A. Controlled Substance Advisory Council (1 appointment)
 - i. Bernauer, Elizabeth
 - ii. Burleson, Michael
 - iii. Carter, Edward Lee
 - iv. Dixon, Aaron
 - v. Gilbert, Aaron
 - vi. Johnican, Stephanie
 - vii. Oyler, Douglas
 - viii. Prather, Elyse

X. CLOSED SESSION DISCUSSION REQUIRED*

- A. Current or Pending Litigation
 - i. 2025 CRP
 - 1. 24-0168, Jeff's Prescription Shop
 - 2. 24-0163, Kroger Pharmacy L-752

*Material not included in Board Packet

XI. ADJOURNMENT

ATTENTION: A portion of the meeting may be held in closed/executive session for the purpose of discussing and deliberating upon open investigations or the review of information required to be conducted in private according to federal and state law. The specific statutory sections authorizing closed session are KRS 61.810(1)(c) KRS 61.878(1)(a) KRS 61.810(1)(j) KRS 61.878(1)(h) KRS 61.810(1)(k). Following discussion and deliberation, any and all action will be taken in open/public session.